[Effectiveness of adjuvant systemic therapy in organ preserving treatment of pT1-2N0M0 breast cancer].
Randomized study was made of 317 patients with early stages (pT1-2N0M0, tumor size of 0.1-3.0 cm in diameter) of infiltrative duct breast cancer, underwent an organ sparing treatment (sectorial resection +/- axillary dissection) either in combination with adjuvant chemotherapy or hormone therapy with tamoxifen or without them. It was shown that probability of recurrence development (in residual breast and regional nodes) was practically similar in women underwent organ sparing treatment if tumor size was not more than 3 cm. It was also found that prescription of adjuvant chemotherapy or hormone therapy with tamoxifen as additional to surgical treatment of tumors within the range from 0.1 to 3.0 cm in diameter did not result in significant reduction in local and regional relapses.
Semiglazov
V F
VF
N.N. Petrov Research Institute of Oncology, Ministry of Health of the RF, St. Petersburg.
Kanaev
S V
SV
Bugrova
I L
IL
Vlasov
A N
AN
D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy* / Q000601:surgery*; D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis / Q000517:prevention & control; D015412:Mastectomy, Segmental; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D009367:Neoplasm Staging; D013629:Tamoxifen / Q000627:therapeutic use; D016896:Treatment Outcome
D018931:Antineoplastic Agents, Hormonal; D013629:Tamoxifen